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Repeated physiological monitoring of comorbidities in heart failure (HF) is pivotal.
This document introduces the main challenges related to physiological monitoring in
the complex multimorbid HF patient, arising during an ESC consensus meeting on
this topic.
Comorbidities are common in patients with heart failure
(HF).1–3 They are increasingly recognized as central com-
ponents of the HF syndrome.4,5 Common comorbidities,
such as diabetes,6–8 hypertension,9 kidney disease,10
atrial fibrillation, chronic obstructive pulmonary dis-
ease,11–13 sleep-disordered breathing,14–16 sarcopaenia,17
angina,18,19 cancer,20 iron deficiency,21 and neuro-psych
ological disorders,22,23 affect symptoms, quality, and
quantity of life of patients with HF as they interfere with
the guideline-driven diagnostic and therapeutic pathways
of HF.24,25
Heart failure patients with comorbidities are usually
older and are frequently under-represented into random-
ized controlled trials.26–28 Often, several comorbidities are
present at the same time in the same patient limiting lead-
ing to poly-pharmacy and limiting the adherence and toler-
ability of guideline-directed life-saving medications, as
well as affecting outcomes29 in ways that are not simply ad-
ditive or easily predictable.30
Furthermore, drugs used to treat comorbidities such as
some antidiabetic medications,31–33 nonsteroidal anti-
inflammatory drugs given for chronic arthritic conditions,
some anti-cancer drugs34,35 and many others can often
worsen HF. As highlighted by the HFA Guidelines on acute
and chronic HF,36,37 the management of comorbidities is a
key component of the holistic care of patients with HF.
Although many comorbidities are managed by other
specialists who follow their own specialist guidelines the
case of the comorbid patient with HF should be sole respon-
sibility of the HF team. This is because HF is in the majority
of cases the principal life-limiting disease and priority to
HF treatment should be given. It becomes evident that in
order to adequately manage HF in the comorbid patient ad-
equate monitoring of the different comorbidities and HF
should be implemented. The frail patient, often as conse-
quence of a chronic disease burden,38 and not just re-
stricted to the elderly,39 may be the most difficult to treat
but also the one least likely to be subject to recruitment
into a clinical trial.40
However, there is still lack of consensus on how to moni-
tor HF and comorbidities, what to monitor (i.e. which pa-
rameter, for which comorbidity), how often and who should
do it (i.e. the HF specialist, the general practitioner, the
nurse). Even for obesity, we do not know what is the opti-
mal advice for weight loss in HF.41 An important issue is also
how to adapt monitoring to the different organization of
care for patients with HF in different Countries. Very sim-
ple physiological measurements are routinely checked, but
rarely systematically monitored. These include heart rate,
blood pressure, electrocardiogram (ECG) pattern, and find-
ings. There is evidence that heart rate should bemonitored
at all visits and treatments should be implemented in order
to reach the target.42 However, this is true for HF patients
in sinus rhythm while no clear evidence on target heart
rate exists for patients in atrial fibrillation.43,44 In HF
patients regardless of heart rhythm, the heart rate should
be always considered in order not to miss cases of
tachycardia-induced cardiomyopathy.
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Despite a wealth of knowledge on the effect of treat-
ments on blood pressure, little is known on the optimal
blood pressure to achieve in both HF reduced (HFrEF) or
preserved ejection fraction (HFpEF).9 Also, it is not clear
whether nocturnal blood pressure should be measured and
monitored routinely, and if there is any role for 24h ambu-
latory blood pressure monitoring. The target for the defini-
tion of hypotension is different between patients with HF
and the general population where lower blood pressure
levels are less well tolerated. However, there is no evi-
dence on the relevance of symptomatic hypotension, or
whether low blood pressure levels are acceptable if the pa-
tient is tolerating it. Patients with different comorbidities
should be monitored for hypotension as this can cause po-
tentially fatal events in patients with underlying coronary
artery disease or in those with significant carotid
atherosclerosis.
While an ECG is routinely performed in patients with HF,
there is little evidence on how to monitor ECG patterns,
rhythms, and conduction. There is no guidance on whether
ECGs should be performed opportunistically or whether
they should be routinely performed on regular follow-up.
Wearable devices should be recommended for ECG record-
ings in patients at increased risk of atrial fibrillation (or for
detecting it), frequent ectopy, non-sustained ventricular
tachycardia, heart block, and pauses. Regular ECGs should
be performed in patients with QRS prolongation in order to
detect the adequate timing for cardiac resynchronization
therapy (CRT).
Left ventricular function defines the types of HF and, in
some instances, its prognosis. It is frequently measured
but, in assessing it and its trajectory, the importance of in-
tra- and inter-operator variability is not taken into consid-
eration. Apart from echocardiography, there is no evidence
or guidance when, how and how frequently other imaging
techniques should be used. Important unanswered clinical
questions are the recommendations for routine echo
follow-up in patients with primary or secondary valve
lesions complicating HF, and whether other circumstances
justify routine echo during follow-up. No specific guide-
lines exist on how frequently patients should be re-
checked with and echocardiogram after CRT or after drug
therapy changes.
Functional capacity should be routinely assessed in
transplant patients, transplant candidates as well as
patients with ventricular assist devices given the prognos-
tic value of exercise tolerance, and especially of peak oxy-
gen uptake. Other measurements derived from formal
cardiopulmonary exercise testing, such as VE/VCO2 slope,
exercise oscillatory ventilation, despite offering immense
patho-physiological insight into a patient’s condition, have
a less well-defined role in routine care. The assessment of
functional capacity includes the potential for wearable
devices and the possibility of daily activity monitoring al-
though, in this case, adequate and tested monitoring devi-
ces should be recommended. In comorbid patients, the
remote monitoring and telemedicine—both non-invasive
and using implanted technologies (pulmonary artery pres-
sure monitoring and loop recorders) may help patient man-
agement and avoid multiple clinic visit and optimize
treatment.
Advanced forms ofmonitoring should include plasma bio-
markers, including their diagnostic role, prognostic value,
value as inclusion criteria for certain therapies (e.g. sacu-
bitril/valsartan) and the choice of the optimal biomarkers
for HFrEF or HFpEF. The routine measurement of natri-
uretic peptides is not recommended and it can providemis-
leading information in patients with comorbidities while
routine monitoring for renal function and electrolytes
should be implemented in all patients with HF.45
Specific challenges of monitoring the advanced HF pa-
tient include lung congestion or total body water monitor-
ing, along with prevalent comorbidities, renal impairment,
electrolyte imbalances,46–48 haemoglobin, and serum iron
(with or without transferrin and transferrin saturation),
sleep-disordered breathing, where differentiating central
from obstructive sleep apnoea is essential to make the ap-
propriate diagnosis and choose the adequate therapy,49–51
and monitoring diabetic control. In this latter case, clear
targets that should be necessarily different by those sug-
gested by the diabetologists should be identified in
patients with HF.
An important question that will need to be addressed in
the future is what clinical trials and with what endpoints
will be needed to get the proof for the recommendation for
routine monitoring of implantable devices. All these pend-
ing questions are tackled by the findings of a series of con-
sensus meetings of the Heart Failure Association of the ESC
on comorbidities and on frailty, the first of which is the sub-
ject of this supplement issue of European Heart Journal.
We know that patients who enter trials do better than
patients in routine care,52 and the same is true for registry
participants.53,54 The explanation may simply be the value
to improved care of systematically evaluating patients
which brings to the clinician’s attention the opportunity
and the reasons to intervene and improve therapy. It is our
aim and our challenge to ourselves to provide this ‘best
level of care’ by systematically monitoring all the comor-
bidities of our HF patients and using these opportunities to
optimize ourmedical and device care.
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